Navigation Links
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Date:10/10/2008

on (5% vs. 1%).(5)

Important Safety Information for SEROQUEL XR

SEROQUEL XR is indicated for the acute treatment of depressive episodes in bipolar disorder; acute manic or mixed episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; for the maintenance treatment of bipolar I disorder as adjunct therapy to lithium or divalproex; and acute and maintenance treatment of schizophrenia. Patients should be periodically reassessed to determine the need for continued treatment and the appropriate dose.

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death, compared to placebo (4.5% vs. 2.6%, respectively). SEROQUEL XR is not approved for the treatment of patients with dementia-related psychosis. (See Boxed Warning.)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies of major depressive disorder and other psychiatric disorders. Patients of all ages started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL XR is not approved for use in patients under the age of 18 years. (See Boxed Warning.)

Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with atypical an
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... MA (PRWEB) March 03, 2015 HubCast® ... Supply Chain, today announced the expansion of its Global ... color-matched print to 850 the world’s largest cities across ... Chain extends to 137 countries providing global enterprises ease, ... print procurement process from online order to real-world delivery ...
(Date:3/3/2015)... N.J. , March 3, 2015  Thingee Corporation, ... will be delivering a presentation entitled, "Technology Adoption: Making ... Thriving through Innovations and Technology ,  in ... March 11 to 13, 2015. Audiences looking to learn ... effectively will want to be in the audience for ...
(Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the ... under Chapter 11 of the U.S. Bankruptcy Code in the ... , Santa Ana division (the "Bankruptcy ... are expected to be jointly administered. The Company ... sale process, for all or substantially all of its assets ...
Breaking Biology Technology:Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Thingee to present at 11th Annual Synergistix Users Conference 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4
... Calif., Oct. 5 Sigma-Aldrich Corporation (Nasdaq: ... SGMO ) today announced a major expansion of ... rights to develop and distribute zinc finger DNA ... of protein pharmaceuticals. Additionally, Sigma-Aldrich licensed rights ...
... Abidance Consulting and ... way to protect their facilities both physically and logically from accidental and intentional intrusions. ... Houston, TX (PRWEB) October 5, ... workshops around the country in the next 12 months. These workshops will be targeting physical ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Corporation") ... of the warrant indenture for those warrants issued on ... of the broker warrant certificates for the broker warrants ... the required written notice to holders of such warrants ...
Cached Biology Technology:Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 2Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 3Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement 4Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date 2
(Date:2/5/2015)... N.C. , Feb. 5, 2015  Marken is ... logistics company and has launched a new marketing campaign ... Logistics Organization (CLO).  The new campaign focuses on ... patient, protocol and shipments. The first headline ... , aligns Marken,s priorities with its client,s priorities. Marken ...
(Date:2/5/2015)... 28, 2015 New Market Research ... Segment Forecasts To 2020 has Been Added to GrandViewReseach.com ... is expected to reach USD 5.10 billion by 2020, ... Inc. IR cameras help identify the site of tissue ... witness surging demand in medical imaging applications. They have ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... at the National Institutes of Health and the Center ... of intent creating a Global Alliance for Pharmacogenomics. The ... individual responses to medicines, including rare and dangerous side ... doctors optimize the safety and effectiveness of drugs for ...
... the GSI accelerator facility to assess radiation risks that astronauts ... selected because its accelerator is the only one in Europe ... space. To determine possible health risks of manned space flights, ... the effects of ion beams in human cells and organs. ...
... of epilepsy, researchers found one of the bodys own ... pathway in the brain that increases production of a ... Researchers say this may explain why approximately 30 percent ... medications. The study, conducted by researchers at the ...
Cached Biology News:Launching a global alliance for pharmacogenomics 2Missions to Mars 2Brain study may lead to improved epilepsy treatments 2
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Dnase and Rnase free...
...
Biology Products: